Beyond The Printed Page

  1. What Are Sugar-Engineered Antibodies?

    The CEO and founder of Seattle Genetics, Clay Siegall, discusses one of the company’s new technologies, sugar-engineered antibodies (SEAs).

  2. How Seattle Genetics Got Bill Gates And Paul Allen As Investors

    The founder and CEO of Seattle Genetics discusses a number of interesting topics, including how he was able to get the founders of Microsoft as early investors in his company.

  3. The Story Behind Seattle Genetics’ Unintentional-Startup Incubator

    Clay Siegall, the founder of Seattle Genetics, explains how his company became an unintentional-startup incubator for Alder BioPharmaceuticals.

  4. Seattle Genetics Legacy Of Partnering

    The CEO of Seattle Genetics discusses the past, present, and future of some of his company’s partnerships.

  5. Clay Siegall Reveals What Surprised Him Most From Founding Seattle Genetics

    The CEO of Seattle Genetics reveals what surprised him about founding a biopharmaceutical company.

  6. Can Boston And San Francisco Remain The Center Of Biopharma’s Universe?

    Three top biopharmaceutical executives share their ideas on what bio clusters biopharmaceutical executives should be paying attention to for 2018. In addition, insights are provided on other future potential bio hot spots.

  7. Want To Know What 5 Biopharmaceutical CEOs Anticipate For 2018 & Beyond?

    Five top biopharmaceutical executives share their thoughts on Big Data, industry trends, personalized medicine, and more in preparing you for what to expect in 2018 – and beyond.

  8. Diverse Perspectives — Insights for 2018 From Biopharma’s Leading Women

    Five female biopharmaceutical industry CEOs share exclusive insights on what to expect for 2018 and beyond.

  9. Five Questions With Lilly’s Daniel Skovronsky, M.D., Ph.D.

    Daniel Skovronsky, M.D., Ph.D., former CEO of Avid Radiopharmaceuticals, sold his company to Eli Lilly and Company in 2010 for $300 million -- $850 million if you add in all the milestones achieved. This successful biopharmaceutical entrepreneur shares personal insights on the process of valuing his company prior to acquisition, his philosophy on optionality, and what if anything he’d do differently.

  10. A Woman Leader On The Subject Of Women As Leaders

    Can women leaders be responsible and liked – at the same time? Sophie Kornowski-Bonnet, head of Roche partnering, discusses her approach to overcoming adversity, leading to an interesting discussion on if there are differences beyond gender for male versus female executives.